Literature DB >> 23354351

Metastatic common bile duct cancer from pulmonary adenocarcinoma presenting as obstructive jaundice.

In Hye Cha1, Jin Nam Kim, You Sun Kim, Soo Hyung Ryu, Jeong Seop Moon, Hye Kyung Lee.   

Abstract

We report an extremely rare case of metastatic common bile duct cancer from pulmonary adenocarcinoma presenting as obstructive jaundice. The patient was a 76-year-old male, who presented with generalized weakness and right upper quadrant pain. Plain chest X-ray noted multiple small nodules in both lung fields. Abdominal computed tomography scan showed a stricture of the mid common bile duct along with ductal wall enhancement. Endoscopic retrograde cholangiography revealed a concentric, abrupt narrowing of the mid-common bile duct suggestive of primary bile duct cancer. However, pathology comfirmed metastatic common bile duct cancer arising from pulmonary adenocarcinoma with immunohistochemical study with thyroid transcriptional factor-1 (TTF-1).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354351     DOI: 10.4166/kjg.2013.61.1.50

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  3 in total

1.  Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma.

Authors:  Nobuaki Ochi; Daisuke Goto; Hiromichi Yamane; Tomoko Yamagishi; Yoshihiro Honda; Yasumasa Monobe; Hirofumi Kawamoto; Nagio Takigawa
Journal:  Onco Targets Ther       Date:  2014-10-07       Impact factor: 4.147

2.  To treat or not to treat: A rare case of response to pembrolizumab-based immunotherapy-chemotherapy in non-small cell lung cancer with acute liver failure due to multiple bile duct metastases.

Authors:  Inna Shaforostova; Sebastian Huss; Mirjam Gerwing; Georg Evers; Annalen Bleckmann
Journal:  Thorac Cancer       Date:  2020-12-27       Impact factor: 3.500

Review 3.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.